药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Siplizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Siplizumab.
Tiludronic acid
Pertuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pertuzumab.
Tiludronic acid
Lucatumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lucatumumab.
Tiludronic acid
Teprotumumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Teprotumumab.
Tiludronic acid
Coltuximab ravtansine
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Coltuximab ravtansine.
Tiludronic acid
XmAb 2513
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with XmAb 2513.
Tiludronic acid
Carotuximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Carotuximab.
Tiludronic acid
AVE9633
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with AVE9633.
Tiludronic acid
Elotuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Elotuzumab.
Tiludronic acid
Motavizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Motavizumab.
Tiludronic acid
Sonepcizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sonepcizumab.
Tiludronic acid
BIIB015
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with BIIB015.
Tiludronic acid
Tocilizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tocilizumab.
Tiludronic acid
Clenoliximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Clenoliximab.
Tiludronic acid
Nimotuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Nimotuzumab.
Tiludronic acid
Ipilimumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ipilimumab.
Tiludronic acid
Canakinumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Canakinumab.
Tiludronic acid
Lumiliximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lumiliximab.
Tiludronic acid
Eldelumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eldelumab.
Tiludronic acid
IMC-1C11
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with IMC-1C11.